Background: Atherosclerotic peripheral artery disease (PAD) is common and results in limitations in quality of life and potential progression to limb loss. Options for therapy include medical therapy, supervised exercise, surgical revascularization, and more recently, endovascular therapies to restore arterial perfusion to the limb. Endovascular revascularization has evolved over the past two decades, from percutaneous transluminal angioplasty (PTA) to self-expanding stents, atherectomy, laser angioplasty, and drug eluting stents. Despite impressive technologic advances, PTA remains the standard of care at many institutions and is the recommended primary treatment modality for femoral-popliteal PAD according to current ACCF/AHA guidelines. However, restenosis after PTA is common. Therefore, a significant clinical need remains for a device that is able to achieve more durable patency than PTA but does not require a permanent implant. 
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(2) incorporated very stringent criteria for bailout stenting; Conclusions: LEVANT 2 represents the first US-inclusive multicenter, randomized, controlled trial to assess the safety and efficacy of a novel drug coated balloon (DCB) compared to PTA as primary therapy for symptomatic PAD on the background of standard medical therapy.
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Background
PAD is a prevalent, world wide problem, affecting ~5-18% of the adult population depending on age 5 and income status 6 . Although a significant proportion of patients with PAD have no reported symptoms from the syndrome 7 , many patients experience disabling inability to walk or, in advanced cases, may suffer limb loss. 8 With the global epidemic of diabetes mellitus, particularly among the elderly 9 , it is anticipated that more severe manifestations of PAD will become more prevalent 10 .
The cornerstone of management of PAD is medical therapy. Antiplatelet therapy is commonly offered to patients with PAD 11 . Exercise, either supervised 12 or performed independently 13 has demonstrated significant improvement in physical function, quality of life and walking distances, even when compared to revascularization 14 . Because of lack of patient compliance, revascularization remains popular. Surgical revascularization is no longer the first line treatment for most patients with PAD due to the associated morbidity and mortality associated with these procedures 11 .
Technology has advanced the field of revascularization for patients with PAD over many years, allowing patients with intermittent claudication and CLI to undergo endovascular procedures as an initial therapeutic strategy. PTA was initially widely performed, but 12-month primary patency rates of 28-37% 15 reduced the enthusiasm for PTA. Stents, which initially were used when procedural complications of PTA occurred, offered superior outcomes particularly for self-expanding stents 16 . Subsequently, several studies demonstrated that primary use of stents offered improved patency than PTA alone 17, 18 .
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As stent use continued, reports of stent fracture began to emerge, raising questions about the durability of these metallic implants 19 . Longer follow up of these devices suggested a direct causal relationship between fracture and loss of patency 20 . Newer generation stents resulted in lower fracture rates 21 . Based upon the dramatic efficacy of anti-proliferative drug coating on coronary stents, and despite initial failure of similar devices in the femoropopliteal segments 22 , a randomized trial comparing a drug coated self expanding stent demonstrated superiority over PTA 23 . Finally, treatment of in-stent restenosis is particularly problematic.
PTA is still the first line standard-of-care at many institutions, and it remains the with safety comparable to standard PTA.
The pivotal LEVANT 2 IDE trial was designed to demonstrate safety and efficacy of DCB in a large population including US centers and to obtain device FDA approval.
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6 Several limitations of historic femoropopliteal studies were carefully considered during this process. For example, in devices studies it is often not possible for the interventionalist to be blinded to treatment group: both stents and DCBs look and feel different than conventional PTA. This limitation makes it difficult to avoid bias from clinical assessments performed by unblinded investigators in follow-up.
Furthermore, it is a subjective decision whether or not to perform a target lesion revascularization (TLR) in cases where symptoms are worsening or restenosis is observed on imaging. The impact of this potential bias was observed in several studies; for example, of subjects with restenosis documented by angiography in the THUNDER study, the decision to reintervene (TLR) was made by the unblinded physician in only 29% of DCB cases but 95% of control PTA cases 1 . Another potential source of unintentional bias was apparent in historic studies that counted bail-out stenting as an immediate primary endpoint failure 29, 30 . In RESILIENT 29 and ZILVER PTX 30 the test group had a 40 and 50% primary endpoint advantage over control immediately following the index procedure. In PTA studies, differences in bailout stenting, for example 4% vs. 22% (p = 0.02) in THUNDER, 1 may also confound interpretation primary outcomes. The LEVANT 2 trial was designed with these historic limitations in mind. with paclitaxel-coated (DCB) vs. uncoated PTA balloons. The study hypothesis is that DCB will provide superior patency and non-inferior safety compared to PTA.
The trial was conducted at 55 centers located in the United States and Europe.
The first subject was enrolled on July 20, 2011 and last subject enrolled on July 10, 2012.
The trial is in compliance with the International Conference on Harmonization Good
Clinical Practice, ISO 14155, and Declaration of Helsinki. One-year follow-up has been completed, and study follow-up, monitoring, and adjudications are ongoing through 5 years.
Study Population
Eligible patients have symptomatic claudication or ischemic rest pain (Rutherford category 2-4) with an angiographically significant atherosclerotic lesion (>70% diameter stenosis) in the superficial femoral and/or popliteal arteries and a patent outflow artery to the foot. Total target lesion length per patient is ≤15 cm and reference vessel diameter is 4 to 6 mm. Inclusion and exclusion criteria are provided in Table 1 .
Study Device
The Lutonix DCB® (Bard Lutonix, New Hope, Minnesota, USA) is an 0.035" guidewire compatable PTA catheter with a semi-compliant balloon that is coated with paclitaxel at a concentration of 2 µg/mm 2 . Paclitaxel is a well-known and widely used anti-proliferative agent, with its' mechanism associated with prevention of mitosis. The
Lutonix DCB coating includes excipient polysorbate and sorbitol to facilitate drug release and tissue deposition. Pre-clinical 26 and pilot randomized clinical data 25 support safety, efficacy, and feasibility of use to treat femoropopliteal arteries. Balloon sizes included in the study are 4.0-6.0 mm in diameter and 40-100 mm in length.
Study Objectives and endpoints
The primary objective of the study is to demonstrate the superior efficacy and Planned secondary endpoints are detailed in Table 2 and include procedural success, revascularizations, alternative thresholds for DUS patency, and change over time in clinical and quality of life measures.
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Sample Size and Statistical Considerations
The pre-specified analysis population includes all evaluable randomized patients.
The primary proportion-based analysis is based on events through the close of the 12 month follow-up window on day 395. Sensitivity analyses are conducted in order to assess the potential impact of missing data, including tipping point, worst case, and
Kaplan-Meier time-to-event analyses.
Expected outcomes for sample size calculations were based on 6 month results observed in the LEVANT 1 trial extrapolated to 12 months (70% vs. 48% for safety and 59% vs. 42% for efficacy). The sample size is based on primary efficacy, for which 405 evaluable patients provides 90% power for superiority based on a two-sided α = 0.05 likelihood ratio chi-square tests of binomial proportions. Randomization of 476 patients accounted for an expected 15% loss of patients from the primary, as observed in recent studies of similar populations. 29, 30 This sample size provides > 95% power for the primary safety endpoint based on a one-sided α = 0.025 Farrington-Manning test of binomial proportions with a 5% non-inferiority margin.
For analysis of demographics and secondary outcomes, continuous variables are compared using t-tests and Wilcoxon nonparametric tests for means and categorical variables are compared using χ2 for proportions.
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Study Procedure
Enrollment and Randomization: Patients signed informed consent, underwent screening, ankle-brachial index determination, walking impairment questionnaire, and a six-minute hall walk test 31 . Arteriography was performed to confirm angiographic inclusion criteria are met (lesion location, length, run-off). Patients meeting entry criteria were required to have a protocol defined pre-dilatation before randomization to study treatments. The pre-dilation balloon was a standard PTA balloon inflated to a diameter approximately 1 mm less than the reference vessel diameter. Following pre-dilatation, patients that were likely to require a stent based on strict angiographic criteria (major flow-limiting dissection or > 70% residual stenosis) were treated and not randomized in order to minimize this confounding variable. Patients unlikely to require a stent based on angiographic assessment after predilation were randomized 2:1 to Lutonix DCB or control PTA. (Figure 1 ). Balloons were sized to target 100% of reference vessel diameter and have length sufficient to treat 5mm proximal and distal to the target lesion and the predilated segment (including overlap of multiple balloons). For patients randomized to DCB, balloons were inflated for as long as necessary to achieve a satisfactory procedural result. Since drug delivery occurs on the first inflation, two DCBs must be deployed to treat longer lesions. A minimum overlap of at least 5mm was required to ensure drug delivery to the entire segment. For subjects randomized to the control arm, treatment was performed with uncoated PTA catheter(s). Use of cutting/scoring balloons was not allowed. Control PTA balloons may be deflated and repositioned to treat longer lesions.
Bailout stenting was allowed in both treatment groups only if the following criteria were met after treatment and prolonged (≥ 2 min ) post-dilatation: residual
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11 stenosis >50% or major flow-limiting dissection AND a translesional pressure gradient >20mmHg (using ≤4F end-hole catheter) or >10mmHg (pressure wire) is measured immediately distal to the target lesion.
After angioplasty, all patients were treated with dual antiplatelet therapy for at least one month and aspirin indefinitely. 
Study management and AE Adjudication
Lutonix, a subsidiary of CR Bard, is the study sponsor and has overall responsibility for the conduct of the study. Another source of potential bias occurs with unblinded clinical follow-up assessment. It is a subjective decision whether or not to reintervene in cases of worsening symptoms or in cases where restenosis is observed on imaging. The LEVANT 2 protocol therefore requires that both the subject and the investigator conducting the follow-up visit be blinded to treatment until the completion of the 12 month visit. Furthermore, since reinterventions may be driven by imaging data rather than worsening of clinical symptoms, the clinical status of the subject is to be assessed prior to reviewing the imaging data. These LEVANT 2 design elements remove the potential for subjective bias at follow-up to affect one year outcomes.
Funding
The LEVANT 2 Trial is sponsored by Lutonix, Inc., a subsidiary of CR Bard. The following endpoints will be assessed at 1, 6, 12, 24, 36, 48 and 60 months: 
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